yang chung

Keywords myelodysplastic syndrome MDS-initiating cell stem cells NHD13 kit hematopoiesis Introduction The myelodysplastic syndromes (MDSs) represent a heterogeneous group of clonal hematopoietic stem cell (HSC) disorders and are a significant cause of morbidity and mortality. In general, the incidence of MDS increases with age, and the median age at diagnosis is 70 years old (Maynadie et al., 1996).

Tumor Biology and Immunology Liat Goldberg, Vijay Negi, Yang Jo Chung, Masahiro Onozawa, Yuelin J. Zhu, Robert L. Walker, Rachel Pierce, Daxesh P. Patel, Kristopher W. Krausz, Frank J. Gonzalez, Margaret A. Goodell, Benjamin A.T. Rodriguez, Paul S. Meltzer and Peter D. Aplan DOI: 10.1158/0008-5472.CAN-21-1027 Published October 2021 This article requires a subscription to view the full text. You may purchase access to this article or login to access your subscription using the links below.

Research Article Liat Goldberg, Vijay Negi, Yang Jo Chung, Masahiro Onozawa, Yuelin J Zhu, Robert L Walker, Rachel Pierce, Daxesh P Patel, Kristopher W. Krausz, Frank J. Gonzalez, Margaret A Goodell, Benjamin AT Rodriguez, Paul S. Meltzer and Peter D Aplan DOI: 10.1158/0008-5472.CAN-21-1027 Abstract Mutations in the isocitrate dehydrogenase 1 (IDH1) and IDH2 genes are frequently observed in a wide variety of hematologic malignancies, including myeloid and T-cell leukemias.